News & Press Articles

CQDM welcomes two new pharma members to its biopharmaceutical research consortium

June 6, 2018


 

BOSTON, June 6, 2018 – CQDM is pleased to announce that Takeda Pharmaceutical Company Limited and Roche have joined the CQDM as new members. Members leverage the consortium’s strength to identify and finance innovative biopharmaceutical research projects from across Canada, with the ultimate goal of enabling the development of better treatments for patients.

« Je salue la venue de ces deux nouveaux membres au sein du CQDM. Les entreprises Takeda Pharmaceutical Company Limited et Roche contribueront à la réussite du consortium, grâce à leur savoir-faire et à leur engagement dans la découverte de médicaments avant-gardistes. Elles contribueront ainsi à la force du réseau unique que représente le CQDM », a mentionné la vice-première ministre, ministre de l’Économie, de la Science et de l’Innovation et ministre responsable de la Stratégie numérique, madame Dominique Anglade.

« L’union fait la force, nous affirme le dicton, et c’est précisément ce que nous démontrera à terme la venue de ces deux nouveaux membres au sein du CQDM, dont l’expertise et le savoir-faire constitueront un atout indéniable pour le consortium. Je me réjouis que les percées médicales et cliniques qui en résulteront bénéficieront à terme à l’ensemble de la population québécoise, notamment grâce au développement de traitements de plus en plus efficaces et de moins en moins invasifs pour les patients », a pour sa part fait savoir le ministre de la Santé et des Services sociaux, monsieur Gaétan Barrette.

“We are very pleased to welcome Roche and Takeda to the CQDM. The participation of these new partners together with other pharma members in CQDM, further enhances our efforts to identify and fund promising technologies”, said Diane Gosselin, President and CEO of CQDM. “Having 12 of the world’s top pharma companies in the consortium also demonstrates the quality and uniqueness of the Quebec collaborative environment to address the most pressing unmet medical needs.”

Since its foundation in 2008, CQDM has successfully pursued the mission to fund the development of innovative tools and technologies that accelerate drug discovery and development. CQDM, with the collaboration of its pharma members, has so far funded 64 innovative research projects in 76 research institutions (both public and private), for a total disbursement of $44M in early stage R&D, $30M in co-funding and $41M of follow-on investments.

“Takeda is very proud to join CQDM to help move forward with its very valuable work of facilitating the development of innovative treatments for the benefit of patients,” said Gamze Yüceland , General Manager of Takeda Canada Inc. “The development of new medicines is such a complex task that it is helped greatly by many partners working constructively together in collaborations such as the CQDM.”

About CQDM

CQDM’s business model is based on a collaborative approach where all stakeholders share the costs of biopharmaceutical research and benefit from its results. CQDM also provides a common meeting ground where academia, governments, and the pharmaceutical and biotechnology industries converge to address numerous complex medical challenges. Industrial members of CQDM include Merck, Pfizer, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Eli Lilly Canada, Janssen, Novartis Pharma Canada, Sanofi Canada, Servier, Roche, Takeda as well as from Quebec’s Ministry of Economy, Science and Innovation (MESI) and from the Government of Canada under the Business-Led Networks of Centres of Excellence Program (BL-NCE). For more information: www.cqdm.org.

About Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and neuroscience therapeutic areas plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. Innovative products, especially in oncology and gastroenterology, as well as Takeda’s presence in emerging markets, are currently fueling the growth of Takeda. Approximately 30,000 Takeda employees are committed to improving quality of life for patients, working with Takeda’s partners in health care in more than 70 countries. For more information, visit www.takeda.com.

- 30 -

For additional information, please contact:

Anne-Sophie Reney
Communications & Marketing
CQDM
Tel:514 766-6661, poste 2188

Catherine W. Audet
Attachée de presse
Cabinet du ministre de la Santé et des Services sociaux
Tél. : 418 266-7171

Gabrielle Fallu
Attachée de presse
Cabinet de la vice-première ministre, ministre de l'Économie, de la Science et de l'Innovation et ministre responsable de la Stratégie numérique
Tél. : 418 691-5650